Advance the next stage of biomarker development
MiND Biosciences is exploring opportunities to accelerate the development and validation of its epigenetic biomarker platform, with an initial focus on MND/ALS and potential future applications across neurodegenerative diseases and beyond.
We welcome conversations with organisations whose scientific, clinical or commercial capabilities can help translate emerging discoveries into useful molecular tools.
Research collaboration
Work with us to investigate disease-associated molecular changes, assess biomarker candidates and strengthen biological understanding. We are interested in complementary expertise in neurodegeneration, epigenetics and molecular analysis.
Clinical validation
Discuss opportunities to evaluate candidate biomarkers in relevant patient cohorts and disease controls. We welcome clinical expertise that can help define useful research questions and future applications.
Diagnostics and assay development
Explore collaboration in assay development, analytical evaluation and scalable testing approaches. Our focus is on building evidence for reliable measurement and potential blood-based applications.
Therapeutic research
Discuss whether future biomarker development could support questions in patient stratification, disease monitoring or treatment-response research.
Strategic investment and development
We welcome discussions with investors and industry partners interested in supporting validation and the longer-term development of MiND’s platform.
Start with a conversation
Tell us about your organisation, area of interest and the opportunity you would like to explore. We can then assess the fit and agree on an appropriate next step.
Further technical information may be made available to prospective partners under a confidentiality agreement, including selected data, validation plans and assay development information.
Partner with us
MiND Biosciences is committed to advancing biomarker discovery through collaboration. We welcome opportunities to work with researchers, clinicians, industry partners and investors who share our vision for earlier, more precise diagnosis.